Government exploring modalities of emergency authorisation of COVID-19 vaccine

Henrietta Brewer
November 22, 2020

The Sinopharm vaccine requires two doses per individual for efficacy.

Drugmakers Pfizer and Moderna have also released data from late-stage trials that shows more than 90% efficacy in their vaccine candidates.

The government is exploring the modalities of emergency authorisation and usage of anti-coronavirus vaccines pending completion of phase-three clinical trial and regular licensure.

In a week of good news regarding the effectiveness of several of the coronavirus vaccine projects, such as Pfizer and Moderna's, today the magazine The Lancet published that the second phase of clinical testing of the formula from the University of Oxford and the pharmaceutical company AstraZeneca is safe in healthy elderly people and provokes an immune response close to 99 percent.

The University of Oxford and AstraZeneca's vaccine included demographics in their study.

Business Insider reported that data from 560 participants of the study suggested that the vaccine was well tolerated across all ages and had similar effects on both young and older adults.

Experts have always been asking Pfizer and Moderna the demographics of their participants but there are no reports about it until now.

"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event". Liu Jingjen, chairman of Chinese pharmaceutical giant Sinopharm, said those who were given the vaccine did not see serious adverse effects, with some complaining of only minor discomfort.

A Chinese Foreign Ministry spokesman Zhao Lijian told a media briefing on Wednesday that five Chinese vaccine candidates are under clinical trials in countries, including the UAE, Brazil, Pakistan and Peru, and phase one and phase two clinical trials of some other vaccines are accelerated.

For his part, without alluding to specific numbers, the head researcher of the study at Oxford University assured that the results of the advanced phase trials, the 3, should be known before Christmas. Russian Federation has registered a second vaccine and working to develop the third one.

Meanwhile, five vaccines are under different phases of clinical trials in India.

While waiting for the full result of Stage 3 human clinical trial, the United Kingdom government has already ordered 100 million doses.

Other reports by iNewsToday